IAM Advisory LLC Buys Shares of 49,184 Pfizer Inc. (NYSE:PFE)

IAM Advisory LLC purchased a new position in Pfizer Inc. (NYSE:PFE) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 49,184 shares of the biopharmaceutical company’s stock, valued at approximately $2,069,000. Pfizer accounts for 0.9% of IAM Advisory LLC’s holdings, making the stock its 13th biggest position.

Several other hedge funds have also modified their holdings of the stock. GoalVest Advisory LLC bought a new position in Pfizer in the 2nd quarter valued at $39,000. Lake Point Wealth Management purchased a new stake in shares of Pfizer during the second quarter valued at $49,000. Harvest Fund Management Co. Ltd grew its holdings in shares of Pfizer by 25,460.0% in the second quarter. Harvest Fund Management Co. Ltd now owns 1,278 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 1,273 shares during the last quarter. Activest Wealth Management purchased a new position in Pfizer in the 2nd quarter worth about $55,000. Finally, KB Financial Partners LLC bought a new stake in Pfizer during the 1st quarter valued at about $62,000. 64.99% of the stock is owned by hedge funds and other institutional investors.

PFE has been the topic of a number of research reports. JPMorgan Chase & Co. set a $42.00 target price on shares of Pfizer in a research report on Friday, November 5th. SVB Leerink reduced their price objective on Pfizer from $50.00 to $48.00 and set a “market perform” rating on the stock in a report on Wednesday, November 3rd. Benchmark upped their target price on Pfizer from $29.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, November 5th. Royal Bank of Canada set a $44.00 price target on Pfizer in a research note on Thursday, July 29th. Finally, The Goldman Sachs Group set a $48.00 price objective on shares of Pfizer in a research note on Thursday, July 29th. Eight investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average price target of $49.00.

NYSE PFE opened at $50.89 on Thursday. The firm has a market cap of $285.64 billion, a PE ratio of 15.15, a price-to-earnings-growth ratio of 1.16 and a beta of 0.72. Pfizer Inc. has a 52 week low of $33.36 and a 52 week high of $52.83. The company has a quick ratio of 1.12, a current ratio of 1.37 and a debt-to-equity ratio of 0.50. The company has a 50 day moving average price of $45.01 and a 200 day moving average price of $43.27.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 2nd. The biopharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.26. Pfizer had a return on equity of 31.66% and a net margin of 27.66%. The business had revenue of $24.09 billion for the quarter, compared to the consensus estimate of $22.82 billion. During the same period in the prior year, the firm posted $0.72 earnings per share. The business’s quarterly revenue was up 134.4% on a year-over-year basis. On average, equities research analysts anticipate that Pfizer Inc. will post 4.2 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 6th. Shareholders of record on Friday, November 5th will be paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 3.07%. The ex-dividend date is Thursday, November 4th. Pfizer’s dividend payout ratio (DPR) is presently 46.43%.

In other news, insider John D. Young sold 150,000 shares of the business’s stock in a transaction dated Thursday, November 11th. The stock was sold at an average price of $50.06, for a total transaction of $7,509,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.05% of the stock is currently owned by company insiders.

Pfizer Company Profile

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Read More: What is the Fibonacci sequence?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.